Literature DB >> 17949071

Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.

Gabriela Barreiro1, Cristiano R W Guimarães, Ivan Tubert-Brohman, Theresa M Lyons, Julian Tirado-Rives, William L Jorgensen.   

Abstract

A virtual screening protocol has been applied to seek non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) and its K103N mutant. First, a chemical similarity search on the Maybridge library was performed using known NNRTIs as reference structures. The top-ranked molecules obtained from this procedure plus 26 known NNRTIs were then docked into the binding sites of the wild-type reverse transcriptase (HIV-RT) and its K103N variant (K103N-RT) using Glide 3.5. The top-ranked 100 compounds from the docking for both proteins were post-scored with a procedure using molecular mechanics and continuum solvation (MM-GB/SA). The validity of the virtual screening protocol was supported by (i) testing of the MM-GB/SA procedure, (ii) agreement between predicted and crystallographic binding poses, (iii) recovery of known potent NNRTIs at the top of both rankings, and (iv) identification of top-scoring library compounds that are close in structure to recently reported NNRTI HTS hits. However, purchase and assaying of selected top-scoring compounds from the library failed to yield active anti-HIV agents. Nevertheless, the highest-ranked database compound, S10087, was pursued as containing a potentially viable core. Subsequent synthesis and assaying of S10087 analogues proposed by further computational analysis yielded anti-HIV agents with EC50 values as low as 310 nM. Thus, with the aid of computational tools, it was possible to evolve a false positive into a true active.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949071      PMCID: PMC2564819          DOI: 10.1021/ci700271z

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  62 in total

1.  Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding.

Authors:  J Ren; C Nichols; L E Bird; T Fujiwara; H Sugimoto; D I Stuart; D K Stammers
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

Review 2.  Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.

Authors:  Giuseppe Campiani; Anna Ramunno; Giovanni Maga; Vito Nacci; Caterina Fattorusso; Bruno Catalanotti; Elena Morelli; Ettore Novellino
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

3.  Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues.

Authors:  Marina Udier-Blagović; Julian Tirado-Rives; William L Jorgensen
Journal:  J Med Chem       Date:  2004-04-22       Impact factor: 7.446

4.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

5.  FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Authors:  Joseph T Kim; Andrew D Hamilton; Christopher M Bailey; Robert A Domaoal; Robert A Domoal; Ligong Wang; Karen S Anderson; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2006-12-06       Impact factor: 15.419

6.  Physics-based scoring of protein-ligand complexes: enrichment of known inhibitors in large-scale virtual screening.

Authors:  Niu Huang; Chakrapani Kalyanaraman; John J Irwin; Matthew P Jacobson
Journal:  J Chem Inf Model       Date:  2006 Jan-Feb       Impact factor: 4.956

7.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes.

Authors:  J Ren; R Esnouf; E Garman; D Somers; C Ross; I Kirby; J Keeling; G Darby; Y Jones; D Stuart
Journal:  Nat Struct Biol       Date:  1995-04

8.  Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

Authors:  Y Hsiou; K Das; J Ding; A D Clark; J P Kleim; M Rösner; I Winkler; G Riess; S H Hughes; E Arnold
Journal:  J Mol Biol       Date:  1998-11-27       Impact factor: 5.469

Review 10.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

View more
  26 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

Review 2.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  From docking false-positive to active anti-HIV agent.

Authors:  Gabriela Barreiro; Joseph T Kim; Cristiano R W Guimarães; Christopher M Bailey; Robert A Domaoal; Ligong Wang; Karen S Anderson; William L Jorgensen
Journal:  J Med Chem       Date:  2007-10-06       Impact factor: 7.446

4.  Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.

Authors:  Elumalai Pavadai; Farah El Mazouni; Sergio Wittlin; Carmen de Kock; Margaret A Phillips; Kelly Chibale
Journal:  J Chem Inf Model       Date:  2016-03-08       Impact factor: 4.956

5.  Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.

Authors:  Sukesh Kalva; D Vinod; Lilly M Saleena
Journal:  J Mol Model       Date:  2014-04-23       Impact factor: 1.810

6.  Ligand-based virtual screening under partial shape constraints.

Authors:  Mathias M von Behren; Matthias Rarey
Journal:  J Comput Aided Mol Des       Date:  2017-03-18       Impact factor: 3.686

7.  Accuracy comparison of several common implicit solvent models and their implementations in the context of protein-ligand binding.

Authors:  E V Katkova; A V Onufriev; B Aguilar; V B Sulimov
Journal:  J Mol Graph Model       Date:  2016-12-21       Impact factor: 2.518

8.  Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization.

Authors:  Julien Michel; Julian Tirado-Rives; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

9.  Small Molecule Subgraph Detector (SMSD) toolkit.

Authors:  Syed Asad Rahman; Matthew Bashton; Gemma L Holliday; Rainer Schrader; Janet M Thornton
Journal:  J Cheminform       Date:  2009-08-10       Impact factor: 5.514

10.  Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations.

Authors:  Jacob G Zeevaart; Ligong Wang; Vinay V Thakur; Cheryl S Leung; Julian Tirado-Rives; Christopher M Bailey; Robert A Domaoal; Karen S Anderson; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2008-06-28       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.